NCI Partners with IMUNON to Expand IMNN-001 into New Cancer Indications
IMNN sits 17% above its 52-week low of $1.47 on elevated volume (2.0× avg).
Summary
IMUNON signed a CRADA with the NCI's CTEP to evaluate IMNN-001 in new solid tumor indications and combination regimens. NCI/CTEP will assume regulatory sponsorship under the NExT Program, and IMNN-001 is the first gene-based immunotherapy selected for partnered clinical development under a CRADA. This leverages NCI's centralized trial infrastructure, allowing capital-efficient expansion beyond ovarian cancer while the company focuses on the Phase 3 OVATION 3 trial. The collaboration validates the platform and could accelerate development without immediate cash outlay, though no financial terms were disclosed. Watch for initiation of new NCI-sponsored trials and any data readouts from these studies.
At the time of this announcement, IMNN was trading at $1.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8M. The 52-week trading range was $1.47 to $5.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.